Sanofi-aventis recently sold Rilutek® (riluzole) to the Switzerland-based pharmaceutical company Covis Pharma Sarl. Riluzole was one of five drugs that Sanofi sold to Covis Pharma for the bargain price tag of $114.6 million. Riluzole is the only FDA-approved drug available for people with ALS. The CEO of Covis Pharma, Jack Davis, ensures that the sale will not compromise the quality of these drugs. Davis said “Covis will continue to supply consistent, top quality, branded pharmaceuticals, ensuring that patients receive the therapeutic care they need.” Riluzole will be distributed through Covis Pharma’s US-based distribution site which is located in Cary, North Carolina.
Click here to read more.Share this: